What drug is ribociclib? Which drug class does it belong to and what are its indications?

Ribociclib is a targeted therapy drug that is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It blocks the cycle progression of tumor cells by inhibiting the activities of CDK4 and CDK6, thereby inhibiting the proliferation of cancer cells. CDK4 and CDK6 are key enzymes in cell cycle regulation. They participate in the transition from G1 phase to S phase and control cell division and proliferation. By inhibiting the activity of these two enzymes, ribociclib can delay the proliferation of tumor cells and limit the growth and spread of tumors.

Indications:

Ribociclib is mainly used to treat breast cancer, especially for patients with HR-positive and HER2-negative advanced or metastatic breast cancer. HR Positive hormone receptor (hormone receptor) indicates that there are hormone receptors on the cancer cells. This type of breast cancer usually responds well to hormone therapy. Therefore, ribociclib is usually used in combination with hormone therapy drugs (such as tamoxifen, anastrozole, etc.) to exert a synergistic effect and further inhibit tumor growth.

1.Advanced breast cancer: Ribociclib is used in combination with hormone therapy drugs to treat HR-positive, HER2-negative advanced or metastatic breast cancer, especially those whose disease has progressed after initial treatment. Through combined use, ribociclib can effectively delay the progression of cancer and improve the survival rate of patients.

2.Adjuvant treatment: In some cases, ribociclib can also be used as adjuvant treatment, especially for high-risk patients, to effectively reduce the risk of tumor recurrence.

Ribociclib helps control the cell cycle by inhibiting CDK4/6, especially in the G1 phase, preventing tumor cells from transitioning from the G1 phase to the S phase, thereby stopping the proliferation of cancer cells. This mechanism of action makes ribociclib very effective in inhibiting breast cancer cells, especially in hormone receptor-positive patients. Its combined use with hormone therapy can significantly improve the therapeutic effect.

Ribociclib as aCDK4/6 inhibitors are mainly used to treat HR positive and HER2 negative breast cancer, especially for patients with advanced or metastatic breast cancer. It helps slow disease progression by inhibiting the proliferation of cancer cells and, when combined with hormone therapy, provides an effective treatment option that significantly improves patient prognosis.

Reference materials:https://us.kisqali.com/